BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells

Tumor Biology

Volumn 32, Issue 5, 2011, Pages 985-995

  Laatio, Liisa ^a   Myllynen, Päivi ^a   Serpi, Raisa ^a   Rysä, Jaana ^a   Ilves, Mika ^a,b   Lappi Blanco, Elisa ^a   Ruskoaho, Heikki ^a   Vähäkangas, Kirsi ^c   Puistola, Ulla ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Angiogenesis; BMP 4; CD105; Cisplatin; Ovarian cancer; TSP 1

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN 4; CARBOPLATIN; CISPLATIN; DOCETAXEL; ENDOGLIN; ENDOTHELIN 1; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PACLITAXEL; PLACENTAL GROWTH FACTOR 2; TAXANE DERIVATIVE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IC 50; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR VASCULARIZATION;

EID: 80052338570     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0200-7     Document Type: Article

References (47)

1. RF Ozols 2006 Challenges for chemotherapy in ovarian cancer Ann Oncol 17 181 187 10.1093/annonc/mdj978 (Pubitemid 43994856)
2. S Ramakrishnan IV Subramanian Y Yokoyama M Geller 2005 Angiogenesis in normal and neoplastic ovaries Angiogenesis 8 169 182 16211363 10.1007/s10456-005-9001-1 1:STN:280:DC%2BD2Mnis1Oqug%3D%3D (Pubitemid 41712846)
3. V Tarallo L Vesci O Capasso MT Esposito T Riccioni L Pastore A Orlandi C Pisano S De Falco 2010 A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization Cancer Res 70 1804 1813 20145150 10.1158/0008-5472.CAN-09-2609 1:CAS:528:DC%2BC3cXisFWjurk%3D
4. L Rosanò F Spinella A Bagnato 2010 The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer Am J Physiol Regul Integr Comp Physiol 299 R395 R404 20538897 10.1152/ajpregu.00304.2010
5. G Taraboletti L Morbidelli S Donnini A Parenti HJ Granger R Giavazzi M Ziche 2000 The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells FASEB J 14 1674 1676 10973914 1:CAS:528:DC%2BD3cXmsFGqurg%3D
6. TG Shepherd BL Thériault MW Nachtigal 2008 Autocrine BMP4 signalling regulates ID3 proto-oncogene expression in human ovarian cancer cells Gene 414 95 105 18372118 10.1016/j.gene.2008.02.015 1:CAS:528: DC%2BD1cXkvVegu7g%3D
7. C Gialeli AD Theocharis NK Karamanos 2011 Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting FEBS J 278 16 27 21087457 10.1111/j.1742-4658.2010.07919.x 1:CAS:528: DC%2BC3MXis1Kltg%3D%3D
8. Z Wang A Ahmad Y Li D Kong AS Azmi S Banerjee FH Sarkar 2010 Emerging roles of PDGF-D signaling pathway in tumor development and progression Biochim Biophys Acta 1806 122 130 20434526 1:CAS:528:DC%2BC3cXntlGjuro%3D
9. Y Yamada T Arao K Matsumoto, et al. 2010 Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer Cancer Sci 101 1886 1890 20491774 10.1111/j.1349-7006.2010.01595.x 1:CAS:528:DC%2BC3cXhtVCktbjP
10. C Giaginis A Tsantili-Kakoulidou S Theocharis 2008 Peroxisome proliferator-activated receptor-gamma ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer PPAR Res 2008 431763 18464916 10.1155/2008/431763 (Pubitemid 351712917)
11. P Perez-Pinera JR Berenson TF Deuel 2008 Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis Curr Opin Hematol 15 210 214 18391787 10.1097/MOH.0b013e3282fdc69e 1:CAS:528:DC%2BD1cXltlSnurg%3D (Pubitemid 351507573)
12. JM Rubatt KM Darcy A Hutson S Bean LJ Havrilesky LA Grace, et al. 2009 Independent prognostic significance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a Gynecologic Oncology Group study Gynecol Oncol 112 469 474 19135712 10.1016/j.ygyno.2008.11.030 1:CAS:528:DC%2BD1MXisVOiurc%3D
13. J Delli Carpini AK Karam L Montgomery 2010 Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer Angiogenesis 13 43 58 20229258 10.1007/s10456-010-9163-3
14. RA Burger 2011 Overview of anti-angiogenic agents in development for ovarian cancer Gynecol Oncol 121 230 238 21215996 10.1016/j.ygyno.2010.11.035 1:CAS:528:DC%2BC3MXjs1Wrs7o%3D
15. A Bagnato F Spinella L Rosanò 2005 Emerging role of the endothelin axis in ovarian tumor progression Endocr Relat Cancer 12 761 772 16322321 10.1677/erc.1.01077 1:CAS:528:DC%2BD28XnvVyjsg%3D%3D (Pubitemid 41815775)
16. K Maeda Y Nishiguchi M Yashiro S Yamada N Onoda T Sawada SM Kang K Hirakawa 2000 Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma Int J Mol Med 5 373 378 10719053 1:CAS:528:DC%2BD3cXisFSlsb0%3D
17. M Yamaguchi K Sugio K Ondo T Yano K Sugimachi 2002 Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer Lung Cancer 36 143 150 11955648 10.1016/S0169-5002(01)00470-6 (Pubitemid 34296556)
18. J Kodama I Hashimoto N Seki A Hongo M Yoshinouchi H Okuda T Kudo 2001 Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor Anticancer Res 21 2983 2987 11712798 1:CAS:528:DC%2BD3MXovVWgt78%3D (Pubitemid 33051163)
19. V Karavasilis V Malamou-Mitsi E Briasoulis E Tsanou E Kitsou N Pavlidis 2006 Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma Int J Gynecol Cancer 16 241 246 16515598 10.1111/j.1525-1438.2006.00316.x
20. AA Secord KM Darcy A Hutson PS Lee LJ Havrilesky LA Grace A Berchuck 2007 Gynecologic Oncology Group study. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 106 221 232 17481705 10.1016/j.ygyno.2007. 03.021 (Pubitemid 46908745)
21. R Wild RP Dings I Subramanian S Ramakrishnan 2004 Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF Int J Cancer 110 343 351 15095298 10.1002/ijc.20100 1:CAS:528:DC%2BD2cXktFeku74%3D (Pubitemid 38649884)
22. XS Zhong LZ Liu HD Skinner Z Cao M Ding BH Jiang 2007 Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells Biochem Biophys Res Commun s358 92 98 10.1016/j.bbrc.2007. 04.083 (Pubitemid 46719085)
23. MC Duyndam MP van Berkel JC Dorsman DA Rockx HM Pinedo E Boven 2007 Cisplatin and doxorubicin repress vascular endothelial growth factor expression and differentially down-regulate hypoxia-inducible factor I activity in human ovarian cancer cells Biochem Pharmacol 74 191 201 17498666 10.1016/j.bcp.2007. 04.003 1:CAS:528:DC%2BD2sXmsFKgt7k%3D (Pubitemid 46890812)
24. GK Siddiqui AB Maclean K Elmasry 2011 Wong Te Fong A, Morris RW, Rashid M, et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer Angiogenesis 14 2 155 161 21221762 10.1007/s10456-010-9199-4 1:CAS:528:DC%2BC3MXmslagsrg%3D
25. J Kigawa S Sato M Shimada M Takahashi H Itamochi Y Kanamori N Terakawa 2001 p53 gene status and chemosensitivity in ovarian cancer Hum Cell 14 165 171 11774736 1:STN:280:DC%2BD38%2FkslSjsQ%3D%3D
26. P Myllynen T Kurttila L Vaskivuo K Vähäkangas 2007 DNA damage caused by benzo(a)pyrene in MCF-7 cells is increased by verapamil, probenecid and PSC833 Toxicol Lett 169 3 12 17218071 10.1016/j.toxlet.2006.11.006 1:CAS:528:DC%2BD2sXhs1Sluro%3D (Pubitemid 46215948)
27. N Nagai M Kinoshita H Ogata, et al. 1996 Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients Cancer Chemother Pharmacol 39 131 137 8995510 10.1007/s002800050548 1:CAS:528:DyaK2sXis1ajsrY%3D (Pubitemid 26400671)
28. LG Presta H Chen SJ O'Connor V Chisholm YG Meng L Krummen M Winkler N Ferrara 1997 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 4593 4599 9377574 1:CAS:528:DyaK2sXmslKqtLg%3D (Pubitemid 27441066)
29. JF Lu R Bruno S Eppler W Novotny B Lum J Gaudreault 2008 Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemother Pharmacol 62 779 786 18205003 10.1007/s00280-007-0664-8 1:CAS:528: DC%2BD1cXht1CjtL3E
30. J Rysä H Leskinen M Ilves H Ruskoaho 2005 Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure Hypertension 45 927 933 15837839 10.1161/01.HYP.0000161873.27088.4c (Pubitemid 40628939)
31. T Majalahti-Palviainen M Hirvinen V Tervonen M Ilves H Ruskoaho O Vuolteenaho 2000 Gene structure of a new cardiac peptide hormone: a model for heart-specific gene expression Endocrinology 141 731 740 10650955 10.1210/en.141.2.731 1:CAS:528:DC%2BD3cXmvFCkuw%3D%3D (Pubitemid 32250498)
32. GJ Rustin I Vergote E Eisenhauer, et al. 2011 Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) Int J Gynecol Cancer 21 419 423 21270624 10.1097/IGC.0b013e3182070f17
33. EA Eisenhauer P Therasse J Bogaerts, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 19097774 10.1016/j.ejca.2008.10.026 1:STN:280: DC%2BD1M%2Fgs12rug%3D%3D
34. L Vaskivuo J Rysä J Koivupera P Myllynen T Vaskivuo K Chvalova R Serpi E-R Savolainen U Puistola K Vähäkangas 2006 Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line Toxicol Appl Pharmacol 216 89 97 16797627 10.1016/j.taap.2006.04.015 1:CAS:528:DC%2BD28XpvV2mtbk%3D (Pubitemid 44402635)
35. BL Thériault TG Shepherd ML Mujoomdar MW Nachtigal 2007 BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells Carcinogenesis 28 1153 1162 17272306 10.1093/carcin/bgm015 (Pubitemid 47062673)
36. TG Shepherd ML Mujoomdar MW Nachtigal 2010 Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion J Ovarian Res 3 5 20187934 10.1186/1757-2215-3-5
37. GP Sorescu H Song SL Tressel J Hwang S Dikalov DA Smith NL Boyd MO Platt B Lassègue KK Griendling H Jo 2004 Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase Circ Res 95 773 779 15388638 10.1161/01.RES.0000145728.22878.45 1:CAS:528:DC%2BD2cXot1aitr0%3D (Pubitemid 39390579)
38. WT Wong XY Tian Y Chen FP Leung L Liu HK Lee CF Ng A Xu X Yao PM Vanhoutte GL Tipoe Y Huang 2010 Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase-2 upregulation: implications on hypertension Circ Res 107 984 991 20724703 10.1161/CIRCRESAHA. 110.222794 1:CAS:528:DC%2BC3cXht1ykurvL
39. J Fang H Nakamura AK Iyer 2007 Tumor-targeted induction of oxystress for cancer therapy J Drug Target 15 475 486 17671894 10.1080/10611860701498286 1:CAS:528:DC%2BD2sXosVSkt7c%3D (Pubitemid 47213870)
40. YJ Wu LL Muldoon EA Neuwelt 2005 The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway J Pharmacol Exp Ther 312 424 431 15496615 10.1124/jpet.104.075119 1:CAS:528:DC%2BD2MXhsVCns7g%3D (Pubitemid 40189538)
41. A Galanis A Pappa A Giannakakis E Lanitis D Dangaj R Sandaltzopoulos 2008 Reactive oxygen species and HIF-1 signalling in cancer Cancer Lett 266 12 20 18378391 10.1016/j.canlet.2008.02.028 1:CAS:528:DC%2BD1cXmsFKlu7g%3D
42. NE Campbell J Greenaway J Henkin RA Moorehead J Petrik 2010 The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer Neoplasia 12 275 283 20234821 1:CAS:528:DC%2BC3cXjt12htbw%3D
43. A Manni T Rager SR Kimball LS Jefferson S Washington X Hu MF Verderame 2007 Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells Int J Oncol 31 1187 1191 17912446 1:CAS:528: DC%2BD2sXhtlKhs77O
44. WJ Rhee CW Ni Z Zheng K Chang H Jo G Bao 2010 HuR regulates the expression of stress-sensitive genes and mediates inflammatory response in human umbilical vein endothelial cells Proc Natl Acad Sci USA 107 6858 6863 20351266 10.1073/pnas.1000444107 1:CAS:528:DC%2BC3cXltFSjurY%3D
45. J Heinke L Wehofsits Q Zhou C Zoeller KM Baar T Helbing A Laib H Augustin C Bode C Patterson M Moser 2008 BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis Circ Res 103 804 812 18787191 10.1161/CIRCRESAHA.108.178434 1:CAS:528:DC%2BD1cXhtFOis73E
46. F Moll C Millet D Noël B Orsetti A Bardin D Katsaros C Jorgensen M Garcia C Theillet P Pujol V François 2006 Chordin is underexpressed in ovarian tumors and reduces tumor cell motility FASEB J 20 240 250 16449796 10.1096/fj.05-4126com 1:CAS:528:DC%2BD28XhsFOmurk%3D (Pubitemid 44933171)
47. D Del Bufalo V Di Castro A Biroccio M Varmi D Salani L Rosanò D Trisciuoglio F Spinella A Bagnato 2002 Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation Mol Pharmacol 61 524 532 11854432 10.1124/mol.61.3.524 (Pubitemid 34171918)